Heron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes lowered the firm’s price target on Heron Therapeutics (HRTX) to $4 from $6 and keeps a Buy rating on the shares. The company reported a Q1 miss with the Zynrelef inflection remaining a “show-me story,” the analyst tells investors in a research note. The firm says Heron’s revenue “pull-through needs to accelerate to maintain public-market interest.”